GlassScriptPhysician profile
William Steadman Farmer
NPI 1396242244
$4,520.81
in general payments reported to CMS, 2019-2025
26 companies · $2,810 in 2025
The $2,810 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $214 · 2023: $256 · 2024: $1,242 · 2025: $2,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.80 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $809.64 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $668.68 | 2022-2025 | |
| Genzyme Corporation | $599.25 | 2024-2025 | |
| Ucb, INC. | $289.81 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $288.10 | 2023-2025 | Ilumya |
| Janssen Biotech, INC. | $223.93 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $219.75 | 2023-2025 | Adbry |
| Kerecis Limited | $193.91 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Amgen INC. | $188.91 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $177.26 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $162.67 | 2024-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $134.63 | 2024-2025 | |
| Lilly USA, LLC | $96.53 | 2024-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $93.72 | 2025 | Zoryve |
| Organogenesis INC. | $59.68 | 2025 | Via Matrix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.89 | 2025 | Cabtreo, Jublia |
| Genentech USA, INC. | $48.60 | 2024-2025 | Xolair, Erivedge |
| Botanix Sb INC | $37.83 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $34.10 | 2025 | Nemluvio |
| Convatec INC. | $26.92 | 2025 | |
| Smith+Nephew, INC. | $26.76 | 2024 | Grafix Xc |
| Incyte Corporation | $22.57 | 2025 | Opzelura |
| Biofrontera INC. | $18.19 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| Urgo Medical North America, LLC | $17.04 | 2024 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Dermavant Sciences, INC. | $14.38 | 2023 | Vtama |
| Lnhc, INC | $14.06 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.